Open-label study to evaluate the safety and efficacy of Ixazomib in combination with
Lenalidomide and Dexamethasone in patients with newly diagnosed multiple myeloma (MM). The
patient population will consist of adult men and women up to 65 years, who have a confirmed
diagnosis of MM who meet eligibility criteria.